Fibrobiologics, Inc. (FBLG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fibrobiologics, Inc., a biotechnology company incorporated in Delaware, on June 9, 2025. The report discloses the appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
Material Changes
On June 9, 2025, the Company appointed Jason D. Davis as Chief Financial Officer, effective immediately. Mr. Davis previously served as CFO at Virax Biolabs (2022-2025) and held various finance leadership roles in the energy sector.
Compensation and Employment Terms
- Base Salary: $350,000 annually.
- Performance Bonus: Eligible for up to 40% of base salary based on company and individual goals.
- Sign-on Bonus: One-time cash payment of $15,000.
- Equity Grant: Stock option for 450,000 shares of common stock under the 2022 Stock Plan. Vesting schedule: 25% on the first anniversary of hire, with the remainder vesting monthly (1/48th per month).
- Severance: In the event of termination without cause or resignation for good reason, Mr. Davis is entitled to nine months of base salary and up to nine months of COBRA premium reimbursement, subject to a signed release.
- Change in Control: If termination occurs within three months prior to or thirteen months following a change in control, unvested options will accelerate.
Risks and Contingencies
The employment agreement is "at-will" and terminable by the Company for any reason with or without notice. The Company has also entered into a standard indemnification agreement with Mr. Davis.
Investor Verification Checklist
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Verify the dilution impact of the 450,000 share option grant against the Company's current outstanding share count.
- Confirm the Company's current cash position to assess the ability to fund the $350,000 annual salary and potential severance obligations.
- Check the Company's 2022 Stock Plan to ensure sufficient shares remain available for the grant.